Abstract
Background Spontaneous bacterial peritonitis (SBP) is complications of end stage liver disease, it associated with morbidity and mortality, the gold standard for diagnosing SBP is an ascitic fluid Polymorphonuclear neutrophil count (PMN) of ≥ 250 cells/mm3, this examination is time consuming and costly. Urine reagent dipstick detecting leukocyte esterase activity has been suggested as quick and affordable substitute. The purpose of this study was to evaluate the CYBOW™ 10 strip’s ability to diagnose SBP.
Methods A Crossectional analytical study was conducted from November 2022 to June 2023. 224 patients with confirmed cirrhotic ascites, aged ≥ 18 years and met inclusion criteria were recruited in the study. By following sterile procedure ascitic fluid was collected, bedside ascitic fluid examination by CYBOW™ 10 reagent strips, and the samples for cytological examination were taken. Ascitic fluid with PMN ≥ 250cells/mm3 was considered positive for SBP, and +1 to +3 of CYBOW™ 10 reagent strip, was used as cut off levels for a positive SBP. By using SPSS version 25, 2 by 2 table was applied to determine the sensitivity (Sn), Specificity (Sp), Positive Predictive value (PPV), and Negative Predictive Value (NPV), and Receiver Operating Characteristic (ROC) was applied to determine the area under the curve of the leukocyte esterase dipstick.
Results On the basis of the ascitic fluid PMN count, 42 (18.75%) individuals had SBP. At cut-off point of +2 CYBOW™ 10 urine reagent strip had Sensitivity of 82.14%, Specificity of 99.39%, PPV of 95.83% and NPV of 96.79%, with AUC of 0.9074.
Conclusion CYBOW™ 10 reagent strip test might be a helpful tool for doctors, when a rapid cell count for SBP diagnosis is not available. These strips are readily available and inexpensive, can be very helpful in areas with low resources and to patients who are unable to pay for cytology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Dodoma provided permission to conduct the study after obtaining ethical clearance from the Directorate of Research and Publications (reference number MA.84/261/02/10). Following that, the administrative departments of Benjamin Mkapa and Dodoma Regional Referral Hospitals approved data collection with reference numbers AB.150/293/01/196 and MA.84/261/02/“A”/59/8, respectively.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
